Balstilimab vs Pembrolizumab berahyaluronidase alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Balstilimab

Developed by Agenus Inc. and partners

Phase 2 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2030 · NCT06322108 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT05722015 · Phase 3 · active, not recruiting

Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.

Next expected readout: December 2029 · NCT07190248 (registry estimate)

Reported efficacy

Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)

Result source: NCT05722015

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBalstilimabPembrolizumab berahyaluronidase alfa
PFS, median—Not reported—Trial running · NCT05722015
OS, median—Not reported—Trial running · NCT05722015
ORR—Not reported64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752
Duration of response, median—Not reported—Trial running · NCT05722015

PFS, median

Balstilimab
—Not reported
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015

OS, median

Balstilimab
—Not reported
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015

ORR

Balstilimab
—Not reported
Pembrolizumab berahyaluronidase alfa
64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752

Duration of response, median

Balstilimab
—Not reported
Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Balstilimab: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Balstilimab: 0 of 4 rows · Pembrolizumab berahyaluronidase alfa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPembrolizumab berahyaluronidase alfa
Dropout rate
n/a: no completion milestonea
NCT05722015 · Phase 3 · combination
show 1 more result
n/a: no completion milestone
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—a
NCT05722015 · Phase 3 · combination
show 1 more result
—
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
39%a
NCT05722015 · Phase 3 · combination
show 1 more result
42.9%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
anaemia 58.2%
neutropenia 41.8%
leukopenia 29.5%
NCT05722015 · Phase 3 · combination
show 1 more result
neutropenia 46.4%
anaemia 42.9%
constipation 39.3%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab berahyaluronidase alfa

ORR 64.3% (n=28) vs 18.2% (n=11) Pembrolizumab
responder rate · % of participants
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Balstilimab's landscape · Pembrolizumab berahyaluronidase alfa's landscape